Related Experiment Video
Updated: Oct 22, 2025
Preparation of Exosomes for siRNA Delivery to Cancer Cells
Published on: December 5, 2018
Engineering Exosomes Endowed with Targeted Delivery of Triptolide for Malignant Melanoma Therapy
Liangdi Jiang1,2, Yongwei Gu1, Yue Du1,2
1Department of Pharmacy, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.
Abstract:
Malignant melanoma is considered the most aggressive skin carcinoma with invasive growth patterns. Triptolide (TPL) possesses various biological and pharmacological activities involved in cancer treatment. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) can induce cancer cell apoptosis by binding to DR5 highly expressed on cancer cells. Exosomes are natural nanomaterials with low immunogenicity, nontoxicity, and excellent biocompatibility and have been extensively used as emerging delivery vectors for diverse therapeutic cargos. Herein, a delivery system based on TRAIL-engineered exosomes (TRAIL-Exo) for loading TPL for targeted therapy against malignant melanoma is proposed and systematically investigated. Our results showed that TRAIL-Exo/TPL could improve tumor targetability, enhance cellular uptake, inhibit proliferation, invasion, and migration, and induce apoptosis of A375 cells through activating the extrinsic TRAIL pathway and the intrinsic mitochondrial pathway in vitro. Moreover, intravenous injection of TRAIL-Exo/TPL significantly suppressed tumor progression and reduced the toxicity of TPL in the melanoma nude mouse model. Together, our research presents a novel strategy for high-efficiency exosome-based drug-delivery nanocarriers and provides an alternative dimension for developing a promising approach with synergistic therapeutic efficacy and targeting capacity for melanoma treatment.
Insights
This study developed TRAIL-engineered exosomes loaded with Triptolide (TPL) for targeted malignant melanoma therapy. The novel nanocarrier system effectively inhibited melanoma progression and reduced TPL toxicity in preclinical models.
Area of Science:
- Oncology
- Nanotechnology
- Pharmacology
Background:
- Malignant melanoma is an aggressive skin cancer.
- Triptolide (TPL) shows anti-cancer properties.
- Exosomes are biocompatible nanocarriers for drug delivery.
Purpose of the Study:
- To develop and investigate TRAIL-engineered exosomes (TRAIL-Exo) loaded with TPL for targeted melanoma therapy.
- To evaluate the efficacy and safety of TRAIL-Exo/TPL in vitro and in vivo.
Main Methods:
- Engineered exosomes with TRAIL for enhanced targeting.
- Loaded exosomes with Triptolide (TPL).
- Evaluated cellular uptake, proliferation, invasion, migration, and apoptosis in A375 melanoma cells.
- Assessed tumor suppression and toxicity in a melanoma nude mouse model.
Main Results:
- TRAIL-Exo/TPL improved tumor targeting and cellular uptake.
- Inhibited proliferation, invasion, and migration of A375 cells.
- Induced apoptosis via extrinsic and intrinsic pathways.
- Significantly suppressed tumor progression and reduced TPL toxicity in vivo.
Conclusions:
- TRAIL-Exo/TPL represents a novel, high-efficiency exosome-based nanocarrier for melanoma treatment.
- This approach offers synergistic therapeutic efficacy and targeting capacity.
- Provides a promising strategy for developing advanced melanoma therapies.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:36Overview of Exosomes
Stahl et al. discovered exosomes in 1983, but the exosomes were initially considered waste products released from the...